Key facts
- This page summarizes Tsontcho Ianchulev's Form 4/A - Amendment filing for EYENOVIA, INC. (EYEN).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 29 Apr 2025, 19:52.
Tsontcho Ianchulev - 21 Apr 2025 Form 4/A - Amendment Insider Report for EYENOVIA, INC. (EYEN)
- Reporting relationship
- Director
- Issuer ticker
- EYEN
- Reported as of
- 21 Apr 2025
- Net transaction value
- $0
- SEC form
- 4/A - Amendment
- Accepted by SEC
- 29 Apr 2025, 19:52:41 UTC
- Original report date
- 23 Apr 2025
- Prior SEC filing
- 14 Jun 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Tsontcho Ianchulev
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Tsontcho Ianchulev filed Form 4/A - Amendment for EYENOVIA, INC. (EYEN) on 29 Apr 2025.
Change
- Previous filing in this sequence was filed on 14 Jun 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4/A - Amendment disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
EYEN
transaction
Common Stock, par value $.0001
Award
- Transaction value
- $0
- Shares
- +5,000
- Change %
- +98%
- Price
- $0.000000
- Shares after
- 10,122
- Date
- 21 Apr 2025
- Ownership
- Direct
- Footnotes
- F1, F2
EYEN
holding
Common Stock, par value $.0001
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 7,583
- Date
- 21 Apr 2025
- Ownership
- By Private Medical Equity, Inc.
- Footnotes
- F3
EYEN
holding
Common Stock, par value $.0001
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 75
- Date
- 21 Apr 2025
- Ownership
- By The Meliora Trust
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Represents restricted stock units that will fully vest upon the closing of the Issuer's proposed business combination with Betaliq, Inc. Vesting is subject to the Reporting Person's continued service to the Issuer.
Footnote F2
On January 31, 2025, the Issuer effected a reverse stock split of its common stock at a ratio of 1-for-80 (the "Reverse Split"). The Reporting Person's ownership of the Issuer's securities has been adjusted to reflect the impact of the Reverse Split.
Footnote F3
The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
SEC remarks
This Form 4/A is being filed to correct a clerical error in the original Form 4 filed on 04/23/2025. The original filing incorrectly reported the amount of securities beneficially owned directly by the Reporting Person. All other information in the original filing remains unchanged.